WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or ...

Luckily, 2025 has given werewolf enthusiasts one of the best stories focusing on the supernatural beasts in recent memory, and it’s a shame that many might have missed it. Earlier this year, writer ...

Peter Stumpp's alleged crimes and execution remain one of the most legendary — and disputed — werewolf trials in history Sean Neumann is a reporter at PEOPLE. He has been working at PEOPLE since 2019.

As of Wednesday, December 17, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 8.80%, which has investors questioning if this is right time to sell.

Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) ...

On December 18, 2025, Werewolf Therapeutics reported a pipeline update and 2026 business priorities centered on its INDUKINE and INDUCER platforms, highlighting preliminary clinical data and a shift ...

WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering the development of therapeutics engineered to stimulate the ...

Marvel Studios’ oddball Halloween horror special Werewolf by Night opens on a stylized art fresco of the Avengers. A voice-over explains that we’re all familiar with certain events in the world of ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Following the official Marvel Cinematic Universe debut of fan-favorite villain Mephisto, it seems like Marvel Studios is ready to embrace more of the MCU’s supernatural side. That’s why, after more ...